PARIS, Feb 15, 2009 (AFP) - The world's largest experiment using gene therapy to combat the AIDS virus has yielded "a major advance," demonstrating that the technique is both beneficial and safe, scientists said on Sunday.
Data from an advanced phase of the test process confirms that the quest to use transplanted genes to roll back the human immunodeficiency virus (HIV) is valid, they said.
Doctors led by Ronald Mitsuyasu of the University of California in Los Angeles recruited 74 HIV-infected volunteers for the experiment, whose results are reported online by the journal Nature Medicine.
Half the group were given blood stemcells that had been infiltrated by a crippled virus containing a key gene, while the other were given a harmless lookalike substance.
The gene encodes something called an RNA enzyme, or ribozyme for short -- a small molecule that, like a spanner thrown into a machine, is intended to block HIV from replicating once it infects a cell.
Stemcells are progenitor cells, which means that when they replicate, future generations of those cells will carry the same genetic code.
The goal was to see whether these novel stemcells, by being shielded from HIV thanks to the ribozyme, would survive the body's immune defences and whether HIV, denied a haven for reproduction, would retreat.
Forty-eight weeks after the so-called OZ1 experiment began, there was no statistical difference between those who had received the gene and those who were given the placebo.
But at the 100-week mark, there was encouraging news: in the gene group, the viral count was significally lower. And the count of CD4 cells -- immune cells that are depleted by HIV -- was higher.
The stock of new blood cells, though, became rather depleted. Four weeks after they were introduced, a DNA test found the modified cells were present in 94 percent of participants in the OZ1 group, which fell to 12 percent by week 48 and to just seven percent at week 100.
None of the gene group experienced any adverse reaction to the therapy.
The treatment "is safe and has efficacy, albeit modest," the study says.
"It shows the potential of the gene therapy approach for the treatment of HIV and represents a major advance in the field... [it] can be developed as a conventional therapeutic product."
Gene therapy arose in the latter years of the Nineties as a golden dawn in medical research.
It conjured a vision whereby a gene, slotted into cells, would either correct a flawed gene that caused disease or, as in the case of the OZ1 trial, block progression of a pathogen.
But the prospects suddenly darkened when an 18-year-old American, Jesse Gelsinger, tragically died in an experiment in 1999 to reverse a rare metabolic disorder. In several other incidents, gene-based treatments caused leukaemia.
Amid a tightening of regulatory oversight, gene therapy has only recently yielded what appears to be its first cures, reviving the immune systems of children with severe combined immunodeficiency, or SCID.
In the field of HIV gene therapy, scientists are exploring more than half a dozen avenues for delivering genes to thwart the AIDS virus.
If HIV gene therapy works, doctors hope patients may be able to scrap, or at least reduce, their regimen of antiretroviral drugs.
These powerful compounds can have toxic side effects, develop viral resistance and have to be taken for the rest of one's life.
In an interview with AFP, Mitsuyasu said this experiment was a Phase II trial in the long, three-phase process to test prototype treatments for safety and effectiveness.
He said he would not put the technique to the final, third phase of the process. Instead, the team would learn from its experience, modify the technique and start again with tests on a smaller group of volunteers.
Mitsuyasu was upbeat.
"I think it gives some hope to this approach being used in HIV and perhaps in other diseases as well, in cancer and congenital defects where we know that there is a gene that might be replaced or fixed," he said.
"It's a positive finding for the field, and should move the field forward."
090215
AF090206
Copyright ©AFP 2009. All Rights Reserved. AFP articles contained on the AEGiS web site may not be reproduced, distributed, transmitted, displayed, published or broadcast without AFP's prior written permission. You may make one copy of each article for your personal, non-commercial use only; more copies would require AFP's prior written permission obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP photos or materials. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP stories, photos or graphics. http://www.afp.com/
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.